# Nikhil C. Munshi

Source: https://onco.cc/people/nikhil-munshi/  
OnCo record `nikhil-munshi` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KarMMa, which brought idecabtagene vicleucel, the first CAR-T for myeloma, to approval.

## Summary

Nikhil Munshi was principal investigator of KarMMa, the pivotal trial showing the BCMA-directed CAR-T idecabtagene vicleucel produces responses in nearly three-quarters of heavily pretreated myeloma patients, leading to the first CAR-T approval in the disease, and of KarMMa-3 comparing it with standard regimens. His laboratory studies myeloma genomics and he led the meta-analysis establishing MRD negativity as a surrogate for survival.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; car-t; genomics
- Role: Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute
- Specialisms: Multiple myeloma; CAR T-cell therapy; Myeloma genomics; Minimal residual disease

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Munshi%20NC%5BAuthor%5D%20myeloma%20idecabtagene

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- institutions: [Dana-Farber Brigham Cancer Center](https://onco.cc/institutions/dana-farber/)
- trials: [KarMMa-3](https://onco.cc/trials/karmma-3/)
- key papers: [KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma](https://onco.cc/key-papers/paper-karmma-3-ide-cel-nejm-2023/)

---
JSON: https://onco.cc/api/v1/entities/nikhil-munshi.json